Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO1 | P15559 | 1/20 | 0.56 |
| ▸ | ACACB | O00763 | 12/20 | 0.54 |
| ▸ | ACACA | Q13085 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CRHBP | P24387 | 1/20 | 0.47 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8285884 | 0.85 | ACACB (0.56) | ACACBACACA | |
| SCHEMBL23209638 | 0.82 | NQO1 (0.58) | NQO1ACACBACACALMNAHPGD | |
| SCHEMBL683602 | 0.79 | NQO1 (0.67) | NQO1ACACBACACAKMT2AMEN1 | |
| SCHEMBL12203937 | 0.79 | NQO1 (0.67) | NQO1ACACBACACAHPGDALDH1A1 | |
| SCHEMBL8286103 | 0.78 | NQO1 (0.54) | NQO1ACACBACACALMNAKMT2A | |
| SCHEMBL17790170 | 0.78 | TP53 (0.49) | ACACBACACALMNAALDH1A1 | |
| SCHEMBL17790232 | 0.78 | TP53 (0.49) | ACACBACACALMNAALDH1A1 | |
| SCHEMBL17790207 | 0.78 | TP53 (0.49) | ACACBACACALMNAALDH1A1 | |
| SCHEMBL13462356 | 0.77 | CA1 (0.56) | ACACBALDH1A1KMT2AMEN1 | |
| SCHEMBL327954 | 0.77 | CA1 (0.56) | ACACBALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3215510-B1 | SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL R&D INVEST S A (PT) | 2023-06-07 | — | — | EP | disclosed |
| US-8883824-B2 | 3-(4-aminophenyl)-2-furancarboxylic acid derivative and pharmaceutically acceptable salt thereof | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2014-11-11 | — | — | US | disclosed |
| US-8470813-B2 | Thiazoline and oxazoline derivatives and their methods of use | ABBVIE INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120059012-A1 | 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-03-08 | — | — | US | disclosed |
| WO-2010131669-A1 | 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | 大日本住友製薬株式会社 (JP) | 2010-11-18 | — | — | WO | disclosed |
| US-20100190776-A1 | Thiazoline and Oxazoline Derivatives and Their Methods of Use | ABBOTT LABORATORIES (US) | 2010-07-29 | — | — | US | disclosed |
| US-7683084-B2 | Thiazoline and oxazoline derivatives and their methods of use | ABBOTT LABORATORIES (US) | 2010-03-23 | — | — | US | disclosed |
| EP-2038278-A2 | THIAZOLINE AND OXAZOLINE DERIVATIVES AND THEIR METHODS OF USE | Abbott Laboratories (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20080070929-A1 | THIAZOLINE AND OXAZOLINE DERIVATIVES AND THEIR METHODS OF USE | ABBVIE INC. | 2008-03-20 | — | — | US | disclosed |
| WO-2008002956-A2 | THIAZOLINE AND OXAZOLINE DERIVATIVES AND THEIR METHODS OF USE | ABBOTT LABORATORIES (US) | 2008-01-03 | — | — | WO | disclosed |
| US-20070111995-A1 | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors | GLAXO GROUP LIMITED (GB) | 2007-05-17 | — | — | US | disclosed |
| WO-2005058892-A1 | PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111995-A1 | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors | PDE4B, PDE3B, PDE4A | NQO1 362/4885ACACB 3593/4885ACACA 3261/4885 |
| US-20120059012-A1 | 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ACSL3, SLCO4C1, SLC38A7 | NQO1 1314/4885ACACB 456/4885ACACA 278/4885 |
| US-20100190776-A1 | Thiazoline and Oxazoline Derivatives and Their Methods of Use | OXA1L, CYP3A7, ABAT | NQO1 223/4885ACACB 452/4885ACACA 779/4885 |
| US-20080070929-A1 | THIAZOLINE AND OXAZOLINE DERIVATIVES AND THEIR METHODS OF USE | OXA1L, CYP3A7, ABAT | NQO1 223/4885ACACB 452/4885ACACA 779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.